By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Verastem, Inc. 

215 First Street
Suite 440
Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-858-0338 Fax: n/a


Company News
Verastem (VSTM) To Present At Upcoming Investor Conferences 1/27/2016 9:21:17 AM
Verastem (VSTM) To Present Scientific Data Supporting FAK Inhibition In Combination With Immune Checkpoint Inhibitors At Immunotherapy World 2016 1/22/2016 6:44:43 AM
Washington University in St. Louis Initiates Clinical Study Of Verastem (VSTM)’s VS-6063 In Combination With Merck & Co. (MRK)’s Pembrolizumab And Gemcitabine In Pancreatic Cancer 1/6/2016 11:23:46 AM
Verastem (VSTM) Reports Third Quarter 2015 Financial And Corporate Results 11/9/2015 11:48:55 AM
Verastem (VSTM) To Present Preclinical Data At SITC 2015 11/4/2015 11:36:03 AM
Verastem (VSTM) To Present Preclinical Data At The 2015 EORTC-National Cancer Institute-AACR International Conference On Molecular Targets And Cancer Therapeutics 10/27/2015 1:09:51 PM
Verastem (VSTM) Slashes Half Its Workforce After Cancer Drug Fails in Mid-Stage Trial 10/8/2015 3:38:01 PM
Verastem (VSTM) Stops Study of Experimental Cancer Therapy; Stock Plunges 9/28/2015 7:12:56 AM
Verastem (VSTM) Announces New Research Published In The Journal Cell That Highlights The Potential Of FAK Inhibition To Enhance The Efficacy Of Anti-Tumor Immunotherapy 9/25/2015 10:23:01 AM
Verastem (VSTM) To Present Preclinical Data At ESMO/ECCO 2015 9/17/2015 1:26:37 PM